Xencor slides amid plans for early-stage trial data for kidney cancer drug
Source: SeekingAlpha
2025-10-14 13:29:54 ET
More on Xencor
- Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release
- Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
- Seeking Alpha’s Quant Rating on Xencor
- Historical earnings data for Xencor
- Financial information for Xencor
Read the full article on Seeking Alpha
For further details see:
Xencor slides amid plans for early-stage trial data for kidney cancer drug
Xencor Inc.
NASDAQ: XNCR
XNCR Trading
1.04% G/L:
$11.62 Last:
256,311 Volume:
$11.72 Open:
XNCR Latest News
XNCR Stock Data
$902,628,328
68,011,331
N/A
68
N/A
Biotechnology & Life Sciences
Healthcare
US
Pasadena
